Table: Sawai Pharmaceutical -Q1 group results (IFRS)

SAWAI group

06/08/2020 05:00

Aug 6 (Reuters)- 
              Sawai Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Jun 30, 2020        Jun 30, 2019     Mar 31, 2021 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               43.94               47.13           200.20    
                   (-6.8 pct)          (+4.1 pct)       (+9.7 pct)  
  Operating            6.88                8.89            26.85    
                   (-22.6 pct)         (+21.4 pct)      (+0.2 pct)  
  Pretax               6.81                8.90            26.55    
                   (-23.4 pct)         (+21.1 pct)      (+0.2 pct)  
  Net                  5.47                6.44            20.05    
                   (-15.0 pct)         (+22.4 pct)      (+4.0 pct)  
  EPS Basic        124.95 yen          147.02 yen       457.94 yen  
  EPS Diluted      124.83 yen          146.92 yen                   
  Ann Div                              130.00 yen       130.00 yen  
  -Q2 Div                               65.00 yen        65.00 yen  
  -Q4 Div                               65.00 yen        65.00 yen  
 
  NOTE - Sawai Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T